Associated tags: Pharmaceutical industry, Cancer, Doctor of Philosophy, Patient, Immunotherapy, Safety, NSCLC, Pembrolizumab, Research
Locations: ROCKVILLE, MD, US
Cancer,
Cell,
Safety,
Pharmacokinetics,
Tumor microenvironment,
Doctor of Philosophy,
IND,
Knowledge,
Entrepreneurship,
ADCC,
Phagocytosis,
Macrophage,
CSO,
CD16,
NK,
SIGLEC,
TME “SIGLEC 10 is an immune checkpoint that inhibits the activation of both innate and adaptive immune cells.
Key Points:
- “SIGLEC 10 is an immune checkpoint that inhibits the activation of both innate and adaptive immune cells.
- “ONC-841 is designed to block this immune checkpoint to rejuvenate immune cell activity for tumor destruction within the TME.
- Preclinical studies supporting the IND application demonstrated ONC-841 increased the phagocytosis of cancer cells and improved the function of tumor-infiltrating T cells.
- Additional in vivo syngeneic and xenograft tumor models showed enhanced immune rejection of tumor cells following treatment with ONC-841.
Lung cancer,
Internal medicine,
Stanford Cancer Institute,
Entrepreneurship,
Princeton University,
Immunotherapy,
Oncology,
International Association,
Research,
Cancer,
Doctor of Philosophy,
MD,
Mesothelioma,
CD24,
MacArthur Fellows Program,
Johns Hopkins University,
Principal investigator,
SAB,
Division,
Stanford University,
CSO,
Thymoma,
Pharmaceutical industry “We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.
Key Points:
- “We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.
- By leveraging universal pathways, OncoC4 has the potential to change the treatment paradigm for many common and aggressive cancers with high unmet needs.
- Currently she serves as Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology.
- She is the Principal Investigator on numerous clinical trials and has held advisory board roles with multiple international pharmaceutical companies.
Retrieved on:
Thursday, February 22, 2024
Principal,
BioNTech,
Safety,
Lutetium,
Patient,
Prostate cancer,
Survival,
Disease,
NYU Langone Health,
Cancer,
Pharmaceutical industry ROCKVILLE, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).
Key Points:
- ROCKVILLE, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).
- BNT316/ONC-392 is being jointly developed by BioNTech and OncoC4.
- The trial will initially evaluate the safety of BNT316/ONC-392 in combination with lutetium (177Lu) vipivotide tetraxetan and help inform the preferred dosage.
- The trial will assess whether the combination increases progression free survival over the current standard of care as the primary endpoint.
Retrieved on:
Thursday, January 4, 2024
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California.
Key Points:
- ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California.
- Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4 will present an overview of the company and its pipeline at 11 a.m. Pacific Time on Thursday, January 11, 2024, in the Mission Bay Room (32nd Floor) of The Westin St. Francis Hotel.
- Dr. Yang and Abid Ansari, Chief Financial Officer of OncoC4, will also participate in one-on-one meetings throughout the week.
Retrieved on:
Thursday, September 28, 2023
BioNTech,
GSK,
Bachelor of Science in Human Biology,
GSK plc,
DNA,
IPO,
Partnership,
HIV,
CSO,
Cancer,
MedImmune,
Abid,
Research,
Bristol Myers Squibb,
Doctor of Philosophy,
Sale,
Business administration,
Acquisition,
Genome,
Chemical engineering,
Ofatumumab,
Immune system,
Purdue University,
CPA,
CFO,
Growth,
Entrepreneurship,
BMS,
Master of Business Administration,
Pharmaceutical industry,
Management,
Novartis ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief Financial Officer (CFO), effective immediately.
Key Points:
- ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief Financial Officer (CFO), effective immediately.
- Abid brings over 20 years of expertise in financial strategy and business development for public and private life science companies to OncoC4.
- “We are delighted to welcome Abid, a seasoned CFO to OncoC4’s executive team.
- Abid Ansari, Chief Financial Officer of OncoC4, added, “OncoC4 is pioneering the development of next-generation biologics and immunotherapies for the treatment of solid tumors.
Neoplasm,
SITC,
Fast Track,
NSCLC,
Doctor of Philosophy,
Patient,
Metastasis,
BNTX,
Entrepreneurship,
PD-1,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Tumor microenvironment,
Food,
Vaccine,
Pharmaceutical industry,
BioNTech The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances.
Key Points:
- The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances.
- OncoC4’s CTLA-4 antibody candidate ONC-392 aims to delete immunosuppressive T cells (regulatory T cells, “Tregs”) in the tumor microenvironment, but spare Tregs in healthy tissues.
- "The data presented by OncoC4 on their ONC-392 antibody indicate a differentiated safety profile and encouraging clinical activity in various types of tumors.
- BioNTech will hold the exclusive worldwide commercialization rights for any of these products with participation of OncoC4 in certain markets to be negotiated in the future.
Retrieved on:
Friday, December 30, 2022
MSD,
Cancer,
Clinical trial,
Pembrolizumab,
Merck & Co.,
Doctor of Philosophy,
Research,
Merck Sharp & Dohme Federal Credit Union,
Immunotherapy,
Patient,
PROC,
Nextgen,
Principal,
Pharmaceutical industry,
Merck The patient was dosed at the Women's Cancer Care Associates, LLC, located in Albany New York.
Key Points:
- The patient was dosed at the Women's Cancer Care Associates, LLC, located in Albany New York.
- I am incredibly grateful for the opportunity to serve as the Co-PI on this Phase 2 trial with Dr. Bradley Monk.
- “We are pleased to be making progress on our ONC-392 clinical program with the dosing of our first patient in the PRESERVE-004 trial in the combination arm with KEYTRUDA.
- Dr. Zhang further added, “We are grateful to our partners, Merck and the GOG Foundation for their support of the PRESERVE-004 trial.
Retrieved on:
Friday, December 30, 2022
MSD,
Cancer,
Clinical trial,
Pembrolizumab,
Merck & Co.,
Doctor of Philosophy,
Research,
Merck Sharp & Dohme Federal Credit Union,
Immunotherapy,
Patient,
PROC,
Nextgen,
Principal,
Pharmaceutical industry,
Merck ROCKVILLE, Md., Dec. 30, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed in the Phase 2 combination study of ONC-392, a nextgen target-preserving anti-CTLA-4 antibody and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with platinum-resistant ovarian cancer (PROC) (PRESERVE-004, NCT5446298).
Key Points:
- The patient was dosed at the Women's Cancer Care Associates, LLC, located in Albany New York.
- I am incredibly grateful for the opportunity to serve as the Co-PI on this Phase 2 trial with Dr. Bradley Monk.
- “We are pleased to be making progress on our ONC-392 clinical program with the dosing of our first patient in the PRESERVE-004 trial in the combination arm with KEYTRUDA.
- Dr. Zhang further added, “We are grateful to our partners, Merck and the GOG Foundation for their support of the PRESERVE-004 trial.
ORR,
DLT,
Immune tolerance,
Neoplasm,
RECIST,
Tumor microenvironment,
Nivolumab,
Boston Convention and Exhibition Center,
PH,
GLOBE,
Adenoid cystic carcinoma,
FDA,
Safety,
Pharmacokinetics,
NSCLC,
University,
Cervical cancer,
Triple-negative breast cancer,
Ipilimumab,
Immunotherapy,
Partial-response maximum-likelihood,
CEO,
Ira Pastan,
Huntsman Cancer Institute,
PR,
DCR,
Doctor of Philosophy,
Pembrolizumab,
PD,
Histology,
Therapeutic index,
Toxicity,
Degenerative disease,
Melanoma,
SD,
Society,
SITC,
Patient,
Convention center,
Cancer,
Vaccine,
Pharmaceutical industry,
Palladium,
Medical imaging,
Aluminium The data will be featured in an oral presentation at the Society for Immunotherapy of Cancers (SITC) 37th annual meeting.
Key Points:
- The data will be featured in an oral presentation at the Society for Immunotherapy of Cancers (SITC) 37th annual meeting.
- The recommended Phase 2 dose has been established at 6 mg/kg of ONC-392 in combination with 200 mg of pembrolizumab.
- We are excited to share positive, initial results from the combination therapy portion of the PRESERVE-001 trial at the prestigious annual SITC meeting, said Yang Liu, CEO of OncoC4, Inc.
- In addition, OncoC4 has a pipeline of first-in-class preclinical products focusing on the CD24-Siglecs cancer immune evasion pathway.
Immunotherapy,
CEO,
Pharmacokinetics,
Escape Room,
Part,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
DRS,
Research,
Collection,
Food,
Alveolar soft part sarcoma,
Lung cancer,
GLOBE,
Immune tolerance,
Doctor of Philosophy,
Patient,
Review,
NSCLC,
Pembrolizumab,
Histology,
Degenerative disease,
Safety,
Tumor microenvironment,
HIV disease progression rates,
Fast Track,
Mab,
FDA,
Accelerated approval (FDA),
Therapy,
Priority review,
Cancer,
Pharmaceutical industry,
Vaccine,
PD We are grateful for the Fast Track designation for ONC-392, which underscores the unmet need for new treatment options for patients with PD(L)-1-resistant NSCLC, said Yang Liu, PhD, co-founder, CEO and Chief Scientific Officer of OncoC4.
Key Points:
- We are grateful for the Fast Track designation for ONC-392, which underscores the unmet need for new treatment options for patients with PD(L)-1-resistant NSCLC, said Yang Liu, PhD, co-founder, CEO and Chief Scientific Officer of OncoC4.
- Our Phase 1b dose expansion study is ongoing for multiple indications, including PD(L)1-resistant NSCLC, with pivotal studies being planned in the near term.
- Fast Track designation is intended to facilitate the development and expedite the review of new therapeutics for the treatment of serious or life-threatening conditions where there is an unmet medical need.
- In recently completed Parts A and B of the study, OncoC4 observed promising clinical activity of ONC-392 in PD(L)1-resistant cancer, including NSCLC.
